$XBI $102.99 | -2.1% %
Pipeline Updates
$IOVA +1.4% Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®. source
$MBIO -0.6% Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. source
$GMDA -1.3% Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings. source
$BCRX -6.9% BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH source
$NUVL -1.2% Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor source
Business Updates
$ RVNC +6.2% Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update source
$ICVX -2.5% Icosavax Provides Corporate Update and Anticipated Milestones for 2022 source
$MRSN -3.8% Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones source
$AVIR -1.6% Atea Pharmaceuticals Highlights Strategic Priorities for 2022 source
$ODT -16.8% Odonate Announces Expected Delisting of Its Stock source
$MOR +1.9% Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance source
$CYTK -9.4% Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million source
Posted by EJR/FS
Commentaires